Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.76 |
| ▸ | HTR2B | P41595 | 1/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.55 |
| ▸ | PNMT | P11086 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30304230 | 0.97 | HTR2C (0.76) | HTR2CHTR2BALDH1A1KDM4ETDP1 | |
| SCHEMBL21776394 | 0.84 | ALDH1A1 (0.63) | HTR2CHTR2BALDH1A1KDM4ETDP1 | |
| SCHEMBL18997080 | 0.84 | ALDH1A1 (0.63) | HTR2CHTR2BALDH1A1KDM4ETDP1 | |
| SCHEMBL26212927 | 0.81 | ALDH1A1 (0.63) | HTR2CHTR2BALDH1A1KDM4ETDP1 | |
| SCHEMBL15711293 | 0.80 | HTR2C (0.62) | HTR2CHTR2BALDH1A1KDM4ETDP1 | |
| SCHEMBL9364845 | 0.78 | PNMT (0.64) | HTR2CHTR2BALDH1A1KDM4ETDP1 | |
| SCHEMBL29189184 | 0.78 | PNMT (0.60) | HTR2CHTR2BALDH1A1PNMTCA12 | |
| SCHEMBL12749953 | 0.76 | CA12 (0.56) | HTR2CHTR2BALDH1A1KDM4ETDP1 | |
| SCHEMBL10154039 | 0.75 | PNMT (0.64) | HTR2CHTR2BALDH1A1KDM4ETDP1 | |
| SCHEMBL17049845 | 0.74 | KMT2A (0.65) | HTR2CHTR2BALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | HTR2C 4575/4885HTR2B 4525/4885ALDH1A1 2765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.